Gut-Derived TMAO May Be a Better Biomarker Than BNP for Acute Heart Failure Decompensation | Research

The takeaway

TMAO, a gut microbiota metabolite, was significantly higher in acute decompensated heart failure than stable heart failure and outperformed BNP in distinguishing between the two conditions.

TMAO AUC > BNP (0.875)
TMAO outperformed the current standard biomarker for detecting acute heart failure decompensation

What the researchers found

TMAO had a higher AUC than BNP for discriminating acute decompensated from stable heart failure, establishing it as a potential novel biomarker for detecting heart failure worsening.

Why it matters

Quickly identifying acute heart failure decompensation saves lives. If TMAO outperforms the current gold standard (BNP), it could improve emergency diagnosis and help guide treatment urgency.

How the study worked

Prospective observational study with 162 participants (102 ADHF, 60 SHF), comparing plasma TMAO levels with clinical, echocardiographic, and laboratory parameters.

What this study cannot tell us

Observational study cannot establish causation; moderate sample size; TMAO levels can be influenced by diet and kidney function, which may confound results.

How to read the evidence

Prospective observational study with statistical validation — strong initial evidence but requires multicenter replication.

When this study was published

Published in 2026, representing cutting-edge biomarker research in heart failure diagnosis.

The bigger picture

This adds to the gut-heart axis story — showing that gut microbiota metabolites are not just associated with cardiovascular disease risk but can actively signal acute cardiac events, potentially revolutionizing heart failure monitoring.

Questions still open

Could TMAO-lowering interventions (dietary changes, probiotics) help prevent heart failure decompensation?
Would combining TMAO with BNP create a superior diagnostic panel for acute heart failure?

Common questions

What is TMAO and where does it come from?

TMAO (trimethylamine-N-oxide) is produced when gut bacteria digest certain nutrients from red meat, eggs, and fish. The liver converts the bacterial product into TMAO, which enters the bloodstream.

Could a blood test for TMAO replace current heart failure tests?

Potentially supplement them — this study found TMAO was actually better than BNP (the current standard) at detecting acute heart failure worsening, suggesting it could become part of a combined diagnostic panel.

Read the original research

Trimethylamine-N-Oxide as a Novel Biomarker in Acute Decompensated Heart Failure: A Comparative Study With Stable Heart Failure Patients.

Angiology, 77(4), 448-457

View on PubMed ↗Publisher’s paper ↗

Citation

Ceylan, Yemlihan; Kaya, Muhammed; Saygın, Murat; Alp, Hamit Hakan. (2026). Trimethylamine-N-Oxide as a Novel Biomarker in Acute Decompensated Heart Failure: A Comparative Study With Stable Heart Failure Patients.. Angiology, 77(4), 448-457. https://doi.org/10.1177/00033197251384351